PIK3CA and breast cancer: The FDA has approved a number of mutations for cancer screening or cancer assaying, including mutations in the BRCA1 and BRCA2 genes for ovarian cancer, ALK rearrangements for NSCLC, and alterations in the PIK3CA gene for breast cancer patients [28].